Brief: Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis
26/02/2024 12:04
Feb 26 (Reuters) - Dianthus Therapeutics Inc DNTH.O :
* DIANTHUS THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2
MAGIC
TRIAL OF DNTH103 IN GENERALIZED MYASTHENIA GRAVIS (GMG)
* DIANTHUS THERAPEUTICS INC - TOP-LINE RESULTS FROM THIS
TRIAL ARE
ANTICIPATED IN SECOND HALF OF 2025
Source text for Eikon: ID:nGNXb0dG8S
Further company coverage: DNTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dianthus Therapeutics
See all newsU.S. RESEARCH ROUNDUP- Adobe, Chewy, Mosaic
Brief: Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Dianthus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dianthus Therapeutics Q2 net loss widens as R&D costs rise